These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 27782326)

  • 1. Injury site-specific targeting of complement inhibitors for treating stroke.
    Alawieh A; Tomlinson S
    Immunol Rev; 2016 Nov; 274(1):270-280. PubMed ID: 27782326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New therapeutic and diagnostic opportunities for injured tissue-specific targeting of complement inhibitors and imaging modalities.
    Holers VM; Tomlinson S; Kulik L; Atkinson C; Rohrer B; Banda N; Thurman JM
    Semin Immunol; 2016 Jun; 28(3):260-7. PubMed ID: 27282113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The complement cascade: new avenues in stroke therapy.
    Komotar RJ; Starke RM; Arias EJ; Garrett MC; Otten ML; Merkow MB; Hassid B; Mocco J; Sughrue ME; Kim GH; Mack WJ; Ducruet AF; Connolly ES
    Curr Vasc Pharmacol; 2009 Jul; 7(3):287-92. PubMed ID: 19601853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage.
    Mastellos DC; Reis ES; Yancopoulou D; Hajishengallis G; Ricklin D; Lambris JD
    Immunobiology; 2016 Oct; 221(10):1046-57. PubMed ID: 27353192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotection in stroke by complement inhibition and immunoglobulin therapy.
    Arumugam TV; Woodruff TM; Lathia JD; Selvaraj PK; Mattson MP; Taylor SM
    Neuroscience; 2009 Feb; 158(3):1074-89. PubMed ID: 18691639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic targeting of complement to modify disease course and improve outcomes in neurological conditions.
    Brennan FH; Lee JD; Ruitenberg MJ; Woodruff TM
    Semin Immunol; 2016 Jun; 28(3):292-308. PubMed ID: 27049459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue-targeted complement therapeutics.
    Tomlinson S; Thurman JM
    Mol Immunol; 2018 Oct; 102():120-128. PubMed ID: 30220307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C1, MBL-MASPs and C1-inhibitor: novel approaches for targeting complement-mediated inflammation.
    Beinrohr L; Dobó J; Závodszky P; Gál P
    Trends Mol Med; 2008 Dec; 14(12):511-21. PubMed ID: 18977695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical promise of next-generation complement therapeutics.
    Mastellos DC; Ricklin D; Lambris JD
    Nat Rev Drug Discov; 2019 Sep; 18(9):707-729. PubMed ID: 31324874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement Therapeutics in Autoimmune Disease.
    Thurman JM; Yapa R
    Front Immunol; 2019; 10():672. PubMed ID: 31001274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement in the Homeostatic and Ischemic Brain.
    Alawieh A; Elvington A; Tomlinson S
    Front Immunol; 2015; 6():417. PubMed ID: 26322048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CR2-mediated targeting of complement inhibitors: bench-to-bedside using a novel strategy for site-specific complement modulation.
    Holers VM; Rohrer B; Tomlinson S
    Adv Exp Med Biol; 2013; 735():137-54. PubMed ID: 23402024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics.
    Melis JP; Strumane K; Ruuls SR; Beurskens FJ; Schuurman J; Parren PW
    Mol Immunol; 2015 Oct; 67(2 Pt A):117-30. PubMed ID: 25697848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of post-stroke degenerative and regenerative processes and subacute protection by site-targeted inhibition of the alternative pathway of complement.
    Alawieh A; Elvington A; Zhu H; Yu J; Kindy MS; Atkinson C; Tomlinson S
    J Neuroinflammation; 2015 Dec; 12():247. PubMed ID: 26714866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Lessons to be Learned From the Role of Complement Regulators as Double-Edged Sword in Health and Disease.
    de Boer ECW; van Mourik AG; Jongerius I
    Front Immunol; 2020; 11():578069. PubMed ID: 33362763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulators of complement activation: a patent review (2008 - 2013).
    Larghi EL; Kaufman TS
    Expert Opin Ther Pat; 2014 Jun; 24(6):665-86. PubMed ID: 24640971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemical Approaches to Modulating Complement-Mediated Diseases.
    Iyer A; Xu W; Reid RC; Fairlie DP
    J Med Chem; 2018 Apr; 61(8):3253-3276. PubMed ID: 28977749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection of host cells by complement regulators.
    Schmidt CQ; Lambris JD; Ricklin D
    Immunol Rev; 2016 Nov; 274(1):152-171. PubMed ID: 27782321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement Interception Across Humoral Incompatibility in Solid Organ Transplantation: A Clinical Perspective.
    Biglarnia AR; Ekdahl KN; Nilsson B
    Adv Exp Med Biol; 2015; 865():211-33. PubMed ID: 26306452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The complement system: a potential target for stroke therapy.
    Mocco J; Sughrue ME; Ducruet AF; Komotar RJ; Sosunov SA; Connolly ES
    Adv Exp Med Biol; 2006; 586():189-201. PubMed ID: 16893073
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.